An Open Label Study to Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac (Live Attenuated Rotavirus Vaccine) as a 3-dose Series in Healthy Infants Aged Between 6 Weeks and 8 Weeks in Vietnam
Latest Information Update: 02 Mar 2021
At a glance
- Drugs ORV 116E (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2021 Status changed from recruiting to completed, as per results published in the Vaccine
- 15 Jan 2021 Results published in the Vaccine
- 21 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 May 2019.